StocksMedium•5 November 2026•
1 min read
Formycon AG Records Non-Cash Impairments and Lowers 2026 EBITDA Guidance
Key Facts
1Formycon AG is recognizing non-cash impairments on its FYB201 and FYB202 biosimilar products.
2The company has revised its adjusted EBITDA guidance for fiscal year 2026.
3The revision in guidance is attributed to increased market competition.
Formycon AG is recognizing non-cash impairments on its FYB201 and FYB202 biosimilar products. Benzinga reported that the company has consequently revised its adjusted EBITDA guidance for the 2026 fiscal year.
The revision in financial guidance is attributed to increased market competition within the biosimilar sector. These non-cash impairment charges reflect the impact of the current competitive environment on the valuation of the company's product portfolio.